Abstract
Objective
To compare the effects of two different formulations of glibenclamide (glyburide) combined with metformin on postprandial glucose excursions, and to assess their pharmacokinetics. The formulations were a combination glibenclamide/metformin tablet (Glucovance™; controlled—particle-size glibenclamide and metformin) versus glibenclamide (Micronase®) and metformin (Glucophage®) coadministered separately.
Design
A randomised, double-blind, two-way crossover study in which patients with type 2 diabetes received either glibenclamide/metformin 2.5/500mg tablets or glibenclamide 2.5mg with metformin 500mg twice daily for 14 days. After a 2-week washout, patients were crossed over to the other treatment for 14 days. Patients consumed standardised meals on the days when pharmacokinetic and pharmacodynamic evaluations were performed.
Participants
Forty patients with type 2 diabetes were enrolled; 37 were randomised (18 men, 19 women) and 35 completed the study. Mean age was 58 years; mean body mass index was 31 kg/m2. The baseline glycated haemoglobin (HbA1c) was 9.3% for both treatment groups.
Main outcome measure
Two-hour postprandial glucose excursion (PPGE) was used to assess postprandial glucose dynamics.
Results
Treatment with glibenclamide/metformin resulted in a significantly smaller mean PPGE than was attained by treatment with glibenclamide plus metformin, according to measurements taken after the day 14 afternoon standardised meal (89.5 vs 117.4 mg/dl, p = 0.011). The mean glibenclamide peak concentration (Cmax) was significantly greater (∼16%) after glibenclamide/-metformin treatment on both days 1 and 14. Glibenclamide/metformin treatment was associated with a 2-fold greater area under the concentration-time curve to 3 hours for glibenclamide (AUC3) [p < 0.001], although the AUC over the administration interval was equivalent for both formulations.
Conclusion
In patients with type 2 diabetes, glibenclamide/metformin resulted in lower PPGE, suggesting that the higher glibenclamide AUC3 observed with this formulation may contribute to better postprandial glycaemic control than is attained by glibenclamide plus metformin separately.
Similar content being viewed by others
Notes
Referred to as glyburide in the US.
Use of tradenames is for product identification only and does not imply endorsement.
References
Garber A, Larsen J, Schneider SH, et al. Simultaneous glyburide/metformin therapy is superior to component monotherapy as an initial pharmacologic treatment for type 2 diabetes. Diabetes Obes Metab 2002; 4: 201–8
Marre M, Howlett H, Lehert P, et al. Improved glycaemic control with metformin-glibenclamide combined tablet therapy (Glucovance) in Type 2 diabetic patients inadequately controlled on metformin. Diabet Med 2002; 19(8): 673–80
Donahue SR, Turner KC, Patel S. Pharmacokinetics and pharmacodynamics of a combination glyburide/metformin tablet versus equivalent doses of glyburide + metformin in patients with type 2 diabetes [abstract]. Endocr Pract 2002; 8: 149
Glucovance (glyburide/metformin tablets) prescribing information. Princeton (NJ): Bristol-Myers Squibb Company, 2001
Marathe PH, Arnold ME, Meeker J, et al. Pharmacokinetics and bioavailability of a metformin/glyburide tablet administered alone and with food. J Clin Pharmacol 2000; 40: 1494–502
el Sayed YM, Suleiman MS, Hasan MM, et al. Comparison of the pharmacokinetics and pharmacodynamics of two commercial products containing glibenclamide. Int J Clin Pharmacol Ther Toxicol 1989; 27: 551–7
Ayanoglu G, Witte PU, Badian M. Bioavailability and pharmacodynamics of a sustained-release glibenclamide product (Deroctyl) in comparison to a standard tablet formulation (Euglucon, Daonil). Int J Clin Pharmacol Ther Toxicol 1983; 21: 479–82
Hermann LS, Schersten B, Bitzen PO, et al. Therapeutic comparison of metformin and sulfonylurea, alone and in various combinations: a double-blind controlled study. Diabetes Care 1994; 17: 1100–9
Marena S, Tagliaferro V, Montegrosso G, et al. Metabolic effects of metformin addition to chronic glibenclamide treatment in type 2 diabetes. Diabet Metab 1994; 20: 15–9
Lupi R, Marchetti P, Giannarelli R, et al. Effects of glibenclamide and metformin (alone or in combination) on insulin release from isolated human pancreatic islets. Acta Diabetol 1997; 34: 46–8
Malone JK, Woodworth JR, Arora V, et al. Improved postprandial glycemic control with Humalog Mix75/25 after a standard test meal in patients with type 2 diabetes mellitus. Clin Ther 2000; 22: 222–30
Micronase (glyburide tablets) prescribing information. Kalamazoo (MI): Pharmacia & Upjohn, 2000
Arnqvist HJ, Karlberg BE, Melander A. Pharmacokinetics and effects of glibenclamide in two formulations, HB 419 and HB 420, in type 2 diabetes. Ann Clin Res 1983; 15 Suppl. 37: 21–5
Melander A, Bitzen PO, Faber O, et al. Sulphonylurea antidiabetic drugs: an update of their clinical pharmacology and rational therapeutic use. Drugs 1989; 37: 58–72
Groop LC, Barzilai N, Ratheiser K, et al. Dose-dependent effects of glyburide on insulin secretion and glucose uptake in humans. Diabetes Care 1991; 14: 724–7
American Diabetes Association. Postprandial blood glucose. Diabetes Care 2001; 24: 775–8
Acknowledgements
Funding for the study was provided by the Bristol-Myers Squibb Company, and Drs Donahue and Turner are employed by the Bristol-Myers Squibb Company.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Donahue, S.R., Turner, K.C. & Patel, S. Pharmacokinetics and Pharmacodynamics of Glyburide/Metformin Tablets (Glucovance™) versus Equivalent Doses of Glyburide and Metformin in Patients with Type 2 Diabetes. Clin Pharmacokinet 41, 1301–1309 (2002). https://doi.org/10.2165/00003088-200241150-00004
Published:
Issue Date:
DOI: https://doi.org/10.2165/00003088-200241150-00004